AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) Receives NMPA’s Approval for Patients with Hyperkalaemia

 AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) Receives NMPA’s Approval for Patients with Hyperkalaemia

AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) Receives NMPA’s Approval for Patients with Hyperkalaemia

Shots:

  • The approval is based on four trials assessing Lokelma vs PBO in patients with hyperkalemia treated for up to 12 months
  • The study resulted in a median time of 2.2 hours in achieving normal potassium levels in the blood, 98% achieved normal levels in 48 hours, rapid reduction of potassium in blood as early as one hour with one dose and a sustained treatment effect for up to one year, well-tolerated data
  • Lokelma is an insoluble oral powder formulation that results as a highly selective potassium-removing medicine approved in the US, EU, Canada to treat hyperkalemia and is under review in Japan with expected results in H1’20

Click here to read full press release/ article | Ref: AstraZeneca | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post